Overview
Announcements

Ordinary Rebalance | Solactive China Healthcare Disruption Index | Effective Date 1st September 2023

In the ordinary rebalance, the following composition will be implemented effective open 01.09.2023:

3D MEDICINES INC
3SBIO INC
AKESO INC
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD
ANGELALIGN TECHNOLOGY INC
CANSINO BIOLOGICS INC
CHINA MEDICAL SYSTEM HOLDINGS LTD
CSPC PHARMACEUTICAL GROUP LTD
GENSCRIPT BIOTECH CORP
GIANT BIOGENE HOLDING CO LTD
GRAND PHARMACEUTICAL GROUP LTD
GUSHENGTANG HOLDINGS LTD
HANSOH PHARMACEUTICAL GROUP CO
INNOCARE PHARMA LTD
INNOVENT BIOLOGICS INC
JD HEALTH INTERNATIONAL INC
JOINN LABORATORIES CHINA C-H
KEYMED BIOSCIENCES INC
LIFETECH SCIENTIFIC CORP
LIVZON PHARMACEUTICAL GROUP INC
LUYE PHARMA GROUP LTD
MICROPORT SCIENTIFIC CORP
PING AN HEALTHCARE AND TECHNOL
REMEGEN CO LTD-H
SHANDONG WEIGAO GROUP MEDICAL POLYMER CO LTD
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD
SHANGHAI JUNSHI BIOSCIENCES CO LTD
SHANGHAI MICROPORT MEDBOT GR
SIMCERE PHARMACEUTICAL GROUP
SINO BIOPHARMACEUTICAL LTD ORD
SKB BIO-B ORD H
WUXI APPTEC CO LTD
WUXI BIOLOGICS CAYMAN INC
YSB ORD
ZAI LAB LTD